PTPN1 and type 2 diabetes mellitus: We have chosen two molecules, baicalein and baicalin, for validation of their anti-inflammatory effects, which was motivated by several factors: beyond the proof through network pharmacology that these molecules have anti-inflammatory potential, the two molecules showed a higher affinity for PTP1B compared to the other four, enabling them to combat T2DM through various functions.